Morgan Stanley initiated coverage of Compass Pathways with an Overweight rating and $30 price target. The firm says treatment-resistant depression represents an area of significant unmet need and Compass has generated positive Phase II data for psychedelic therapy COMP360. The firm sees “significant room” for the shares to rise based on upcoming regulatory and data catalysts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Rising High: Exclusive talk with financial services firm Safe Harbor Financial
- COMPASS Pathways Leadership Restructure and Board Reshuffle
- Compass Pathways co-founders depart from board, David Norton named interim chair
- Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
- Here’s What You Missed in Cannabis, Psychedelics This Week
